SOR-007 is under clinical development by Nanology and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SOR-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SOR-007 overview
Paclitaxel is under development for the treatment of pancreatic cyst (mucinous cystic pancreatic neoplasms), pancreatic adenocarcinoma, cutaneous metastasis and actinic keratosis, non-small cell lung cancer and breast cancer. It is a sterile nanoparticulate paclitaxel and administered through intraperitoneal, topical, intracystic, inhalational and intratumoral routes. It was under development for cervical intraepithelial neoplasia, epithelial ovarian cancer and plaque psoriasis. It is developed based on supercritical precipitation (SCP) technology.
It was under development for the treatment of prostate cancer.
Nanology overview
Nanology operates as a clinical stage pharmaceutical development company formed by the collaboration of DFB Pharmaceuticals, CritiTech, and US Biotest to advance its patented submicron particle production technology platform for the treatment of cancer and other serious illnesses. The company’s program includes clinical trials in ovarian, prostate, and pancreatic cancers, pancreatic cysts, cutaneous metastases, and actinic keratosis under affiliate, Soria. In addition, nonclinical studies via nebulized inhalation are underway for the treatment of lung cancer. Nanology is headquartered in Fort Worth, Texas, the US.
For a complete picture of SOR-007’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
